Evidence map›Paper›PMID 33958050›Full record

ArticleMayo Clinic proceedings2021

A Blueprint to Control the SARS-CoV-2 Pandemic.

John C O'Horo, Amy W Williams, Andrew D Badley

Abstract read
In one paragraph

Article in Mayo Clinic proceedings, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

John C O'HoroDepartment of Infectious Diseases, Mayo Clinic, Rochester, MN.
Amy W WilliamsDepartment of Medicine, Mayo Clinic, Rochester, MN.
Andrew D BadleyDepartment of Infectious Diseases, Mayo Clinic, Rochester, MN; Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN. Electronic address: badley.andrew@mayo.edu.

Funding

Prime shock and kill for HIV erradicationR01AI110173 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2014 to 2024
$6.9M
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistence.R01AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2015 to 2019
$2.5M
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistenceR56AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2021 to 2021
$607k
NIAID NIH HHS R01 AI110173NIAID NIH HHS R01 AI120698NIAID NIH HHS R56 AI120698
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Immunity, HerdCommunicable Disease ControlCOVID-19 VaccinesDisease Transmission, InfectiousEarly DiagnosisHumansPublic HealthSARS-CoV-2COVID-19 Vaccines

Identifiers

PMID33958050
PMCPMC7997695

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.